ClinicalTrials.gg
RecruitingNCT07444476SOLARUpdated Nov 13, 2026

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

A Phase 3 interventional study of Salanersen in Spinal Muscular Atrophy, sponsored by Biogen. Recruiting at 10 sites in 4 countries. Open to participants aged 15 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 13, 2026First sites in China, Japan and South KoreaStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
15 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.

Planned enrollment
7th of 21
90 · median 47
Started
2026
with 2 others
Phase 3
9 of 27
3 open now
Registered
26th of 27
by date

Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is the 7th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 in phase 3, and was the 26th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 72 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 57 Muscular Atrophy, Spinal studies recruiting now, 28 (49%) set no upper age limit and 26 (46%) stop at 75 or younger; 45 take children under 18; 11 take healthy volunteers.

This study: 15 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Atrophy, Spinal by Biogen, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen.

Specifically, researchers will learn more about how salanersen works in individuals with SMA who are between the ages of 15 and 60 years old. In most people living with SMA, changes to or a lack of a gene called survival motor neuron 1 (SMN1) - often referred to as gene mutations or variants - affect how this gene works. As a result, their bodies produce less SMN protein. Without enough of this protein, motor neurons and muscles cannot work properly. There is a similar gene called SMN2 that produces SMN protein, but it usually does not produce enough SMN protein on its own to make up for the changes in the SMN1 gene. Salanersen is a drug designed to help the SMN2 gene to make more working SMN protein.

In this study, there will be 2 groups of participants: a group who has never received treatment for SMA before joining this study, and a group who has been treated with risdiplam, an approved drug for SMA . Those participants must not have received any other SMA treatments before and will need to stop their risdiplam treatment for the duration of the study.

The main goal of this study is to learn more about how salanersen affects the participants' motor function. Researchers will use different tests and questionnaires to learn if motor function is changing over the study duration.

The main question researchers want to answer in this study is:

  • For the group who has never been treated for SMA, how much do scores on the HFMSE movement test change at 12 months compared to the beginning of the study? The Hammersmith Functional Motor Scale - Expanded (HFMSE) has 33 activities that are scored which include sitting, lying down, walking, jumping, and more.

Researchers will also learn more about:

  • The effects on participants' motor function and how well their nerves and muscles function.
  • The effects on participants' overall sense of change and how they perform daily activities.
  • How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug.
  • How much salanersen gets into the fluid surrounding the brain and spinal cord.
  • How much salanersen gets into the blood.

This study will be done as follows:

  • First, participants will be screened to check if they can join the study. The screening period may be up to 4 weeks.
  • This is an "open-label" study. This is a study in which the participants, study doctor, and site staff will know that participants are receiving salanersen.
  • All participants will receive salanersen through an intrathecal injection, or one that is given into the fluid surrounding the brain and spinal cord.
  • Participants will receive salanersen once every year for a total of 5 times throughout the study.
  • Including screening, participants will have 17 study visits and 9 telephone calls during this study, which will last up to 61 months in total.
Read the detailed description

The primary objective of the SOLAR study is to evaluate the clinical efficacy of salanersen in participants with SMA who are treatment-naïve or previously treated with risdiplam. The secondary objective of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of salanersen.

03

Conditions studied

  • Spinal Muscular Atrophy
04

Who can participate

Ages eligible
15 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants aged 15 to 60 years, inclusive, at the time of
  • Participants with genetic documentation of 5q Spinal Muscular Atrophy (SMA) (homozygous gene deletion or mutation or compound heterozygous mutation).
  • Participants with clinical signs and symptoms consistent with SMA.
  • Survival motor neuron 2 (SMN2) copy number ≥ 1.
  • Participants with baseline Hammersmith Functional Motor Scale - Expanded (HFMSE) total score of ≥ 10 to ≤ 54.
  • Participants who are able to sit without using support for at least 10 seconds.
  • Participants with no prior treatment with myostatin inhibitors and a willingness to remain off concurrent myostatin inhibitor therapy for the duration of the study.
  • Ambulatory and nonambulatory participants:

    • Ambulatory participants must be able to walk at least 10 meters independently without assistance and are willing and able to complete the 6 Minute Walk Test (6MWT) at Screening.
  • For participants in the treatment-naïve cohort:

    • No prior treatment with an approved SMA Disease Modifying Therapy (DMT) or an drug given for the treatment of SMA.
  • For participants in the risdiplam-treated cohort:

    • Currently receiving risdiplam treatment and have been on once-daily 5 milligrams (mg) risdiplam treatment for at least 6 months prior to Screening.
    • Willing to stop risdiplam therapy for the duration of the study. The last dose of risdiplam must be taken the day before the first dose of salanersen.
    • No prior treatment with nusinersen, onasemnogene abeparvovec-xioi/onasemnogene abeparvovec-brve (OA), other approved DMTs for SMA or investigational drugs given for the treatment of SMA apart from risdiplam.

Key Exclusion Criteria:

  • Respiratory insufficiency at Screening, defined by the medical necessity for invasive or noninvasive ventilation for > 6 hours during a 24-hour period (except for nocturnal bilevel positive airway pressure).
  • Medical necessity for a gastric feeding tube, where the majority of nutrition is provided by this route, as assessed by the site Investigator at Screening.
  • History of brain or spinal cord disease or other (e.g., severe scoliosis) that would interfere with the lumbar puncture (LP) procedures, Cerebrospinal fluid (CSF) circulation, efficacy assessments, or safety assessments (including a history of hydrocephalus or implanted shunt for CSF drainage), as assessed by the Investigator.
  • Hospitalization for surgery, a pulmonary event, or nutritional support within 2 months prior to Screening or plans to undergo elective procedures or surgeries at any time after signing the Informed Consent Form (ICF) through the end of the study. Note: If prior scoliosis surgery has been performed, it must be done at least 1 year prior to Screening.
  • Presence of an active medical issue (e.g., infection, recent fracture) that would make the participant unsuitable for inclusion, as assessed by the Investigator.
  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 90 days or 5 half-lives of the treatment (if known), whichever is longer, prior to Screening. This includes neuromodulation therapy such as spinal cord stimulation.

Note: Other protocol-defined inclusion/exclusion criteria will apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Treatment-Naïve Cohort

    Treatment-naïve participants will receive salanersen 80 milligrams (mg) by intrathecal (IT) lumbar puncture (LP) every 12 months for a total of five doses.

    Drug: Salanersen

  • Experimental
    Risdiplam-Treated Cohort

    Risdiplam-treated participants will receive salanersen 80 mg by IT LP every 12 months for a total of five doses.

    Drug: Salanersen

Interventions

  • Administered Intrathecally

    Also known as: BIIB115

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Total Score in Treatment-Naïve Cohort

    The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities.

    Time frame: At Month 12

Secondary outcomes

  1. Percentage of Participants With ≥ 3-Point Change From Baseline in HFMSE Total Score

    The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities.

    Time frame: Up to Day 1825

  2. Percentage of Participants With ≥ 2-Point Change From Baseline in Revised Upper Limb Module (RULM) Total Score

    The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.

    Time frame: Up to Day 1825

  3. Percentage of Participants With ≥ 30-Meter Change From Baseline in 6-Minute Walk Test (6MWT) Distance (Ambulatory Participants Only)

    The 6MWT is a submaximal exercise test used to assess an individual's functional exercise capacity. It measures the distance covered in 6 minutes on a flat, hard surface, providing valuable information about aerobic capacity and endurance.

    Time frame: Up to Day 1825

  4. Change From Baseline in HFMSE Total Score

    The HFMSE is a tool used to assess motor function in individuals with SMA. Participants will be asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability. The overall score is the sum of the scores for all 33 items, with a maximum score of 66 with higher scores depicting better ability to perform activities.

    Time frame: Up to Day 1825

  5. Change From Baseline in RULM Total Score

    The RULM is developed to assess upper limb functional abilities of participants with SMA. This test consists of a total of 20 upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.

    Time frame: Up to Day 1825

  6. Change From Baseline in Total 6MWT Distance (Ambulatory Participants Only)

    The 6MWT is a submaximal exercise test used to assess an individual's functional exercise capacity. It measures the distance covered in 6 minutes on a flat, hard surface, providing valuable information about aerobic capacity and endurance.

    Time frame: Up to Day 1825

  7. Change From Baseline in Compound Muscle Action Potential (CMAP) Amplitudes

    CMAP is a well validated method for tracking disease progression in neuromuscular disorders such as SMA and amyotrophic lateral sclerosis and has been proposed as a potential biomarker of a therapeutic effect in SMA. CMAPs will be performed for the following nerve-muscle pairs: ulnar-abductor digiti minimi and peroneal-tibialis anterior.

    Time frame: Up to Day 1825

  8. Patient Global Impression of Change (PGI-C) Score

    PGI-C is a self-reported 7-point scale evaluating the participant's perception of change in disease state since baseline. The scale ranges from 1 to 7, where 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; or 7= very much worse. Lower scores indicate clinical improvement, and higher scores indicate disease worsening.

    Time frame: Up to Day 1825

  9. Change From Baseline in SMA Independence Scale - Upper Limb Module (SMAIS-ULM)

    The SMAIS-ULM is a validated tool designed to assess the level of independence in daily activities related to upper limb functionality for individuals with Type II and nonambulant Type III SMA. The 22 items assess upper limb focused tasks across 5 domains of typical daily activities (bathing/hygiene, dressing, eating/drinking, picking up/moving objects, and other tasks) scored on a 3-point scale (0 = I cannot do this at all without help; 1 = I need some help; and 2 = I do not need help). Higher scores indicate greater independence.

    Time frame: Up to Day 1825

  10. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Day 1825

  11. Concentration of Salanersen in Cerebrospinal Fluid (CSF)

    Time frame: Up to Day 1460

  12. Concentration of Salanersen in Serum

    Time frame: Up to Day 1825

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 21 months after the start.

Of 18 phase 3 interventional studies under Muscular Atrophy, Spinal, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 21 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartActual
Sep 8, 2026was Apr 2026
Primary completionEst.
Jun 23, 2028
CompletionEst.
Jun 22, 2032
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 1 site removed — first sites in China, Japan and South Korea
Show 10 added (4 China, 3 South Korea, 2 United States, 1 Japan)
  • Stanford University Medical Center · Palo Alto, United States
  • Peking Union Medical College Hospital · Beijing, China
  • Massachusetts General Hospital · Boston, United States
  • Peking Union Medical College Hospital · Beijing, China
  • Qilu Hospital of Shandong University · Jinan, China
  • Peking Union Medical College Hospital - East Campus · Beijing, China
  • National Hospital Organization Osaka Toneyama Medical Center · Toyonaka, Japan
  • Gangnam Severance Hospital, Yonsei University Health System (Pediatric) · Seoul, South Korea
  • Seoul National University Hospital · Seoul, South Korea
  • Gangnam Severance Hospital, Yonsei University Health System (Adult) · Seoul, South Korea
Show 1 removed
  • Peking Union Medical College Hospital · Beijing, China
across 2 updates, Oct 2, 2026 – Nov 13, 2026
Start date
Apr 3, 2026→Sep 8, 2026 (actual)
Oct 2, 2026
Show all 2 updates
  1. Nov 13, 2026
    8 sites added, 1 site removed — first sites in Japan and South Korea
    Show 8 added (3 China, 3 South Korea, 1 United States, 1 Japan)
    • Massachusetts General Hospital · Boston, United States
    • Peking Union Medical College Hospital · Beijing, China
    • Qilu Hospital of Shandong University · Jinan, China
    • Peking Union Medical College Hospital - East Campus · Beijing, China
    • National Hospital Organization Osaka Toneyama Medical Center · Toyonaka, Japan
    • Gangnam Severance Hospital, Yonsei University Health System (Pediatric) · Seoul, South Korea
    • Seoul National University Hospital · Seoul, South Korea
    • Gangnam Severance Hospital, Yonsei University Health System (Adult) · Seoul, South Korea
    Show 1 removed
    • Peking Union Medical College Hospital · Beijing, China
    + 1 other change: verification date
  2. Oct 2, 2026
    2 sites added — first site in China
    Show 2 added (1 United States, 1 China)
    • Stanford University Medical Center · Palo Alto, United States
    • Peking Union Medical College Hospital · Beijing, China
    Start date Apr 3, 2026→Sep 8, 2026 (now actual)
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07444476
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Sep 8, 2026
Primary completion
Jun 23, 2028 (estimated)
Completion
Jun 22, 2032 (estimated)
Last update
Nov 13, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Salanersen

Start the discussion